Contact: Hariharan Subramanian

PancreaSolve, Inc. Phone: (617) 553-1015 701 Concord Avenue Cambridge, MA 02138 info@pancreasolve.com www.pancreasolve.com



PRESS RELEASE

Dr. Sunil Krishnan of MD Anderson Cancer Center joins the scientific advisory board of PancreaSolve, Inc.

Cambridge, **November 2, 2015**: World renowned pancreatic cancer researcher Dr. Sunil Krishnan joins the scientific advisory board of PancreaSolve.

"We are delighted to have a leading expert on pancreatic cancer such as Dr. Sunil Krishnan on our scientific advisory board," said Dr. Shiva Ayyadurai, Chief Executive Officer of PancreaSolve.

Dr. Sunil Krishnan is Professor in the Department of Radiation Oncology, Division of Radiation Oncology at The University of Texas MD Anderson Cancer Center. Dr. Krishnan is actively involved in patient care and clinical trials on the gastrointestinal cancer service of the Department of Radiation Oncology. His clinical effort is directed towards developing novel therapies for patients with gastrointestinal tumors and finding molecular and imaging biomarkers of response to chemoradiation therapy. He is the principal investigator of several clinical trials focusing on radiation sensitization strategies for these tumors, especially liver, pancreatic and rectal cancers.

PancreaSolve is headquartered in Cambridge, MA. PancreaSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multicombination therapeutics.

CytoSolve is headquartered in Cambridge, MA. CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.